Insider · CIK 0001920509
da Silva Jorge Santos
Files at MLTX (MoonLake Immunotherapeutics). First filing Feb 20, 2024, latest Jul 13, 2026.
In brief
da Silva Jorge Santos files SEC Form 4 as CEO and director at MLTX (MoonLake Immunotherapeutics). Since Feb 20, 2024, da Silva Jorge Santos has reported 0 open-market buys worth $0 and 7 open-market sells worth $19M, the latest filed on Jul 13, 2026.
A track record needs three past buys with six months of prices behind them; da Silva Jorge Santos has 0, so none is measured yet.
The newest scored trade: sold $2.0M of MLTX on Jul 9, 2026, filed Jul 13, 2026, scored 38 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $8.7M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MLTX: MoonLake Immunotherapeutics
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | MoonLake Immunotherapeutics | $2.0M 102,225 shares | -4% | +219% from low-68% from high | |
| 44Moderate | MoonLake Immunotherapeutics | $957k 47,775 shares | -2% | +206% from low-69% from high | |
| 65Notable | MoonLake Immunotherapeutics | $2.8M 150,000 shares | -5% | +188% from low-71% from high | |
| 58Moderate | MoonLake Immunotherapeutics | $3.0M 200,000 shares | -6% | - | |
| 38Weak | MoonLake Immunotherapeutics | $6.8M 123,615 shares | -4% | +193% from low-14% from high | |
| 20Weak | MoonLake Immunotherapeutics | $62k 1,125 shares | -0% | +201% from low-16% from high | |
| 38Weak | MoonLake Immunotherapeutics | $3.6M 60,000 shares | -2% | +258% from low-6% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 30, 2026 | MLTX MoonLake Immunotherapeutics | 150,000 0.20% of outstanding | $3.0M | Jun 30, 2026 | $2.8M |
| Apr 10, 2026 | MLTX MoonLake Immunotherapeutics Inc. | 150,000 0.21% of outstanding | $2.8M | Apr 10, 2026 | none |
| Dec 8, 2025 | MLTX Moonlake Immunotherapeutics | 200,000 0.31% of outstanding | $3.0M | Dec 8, 2025 | none |
| Feb 15, 2024 | MLTX MoonLake Immunotherapeutics | 200,000 0.33% of outstanding | $13M | Feb 15, 2024 | none |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -33,936 | $20.01 | $679k | 2,843,182 | Jul 13, 2026 |
| Jul 10, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -68,289 | $20.02 | $1.4M | 2,774,893 | Jul 13, 2026 |
| Jul 1, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -47,775 | $20.03 | $957k | 2,877,118 | Jul 2, 2026 |
| Apr 10, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -98,127 | $18.41 | $1.8M | 2,976,766 | Apr 14, 2026 |
| Apr 13, 2026 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -51,873 | $18.23 | $946k | 2,924,893 | Apr 14, 2026 |
| Jan 7, 2026 | MLTX MoonLake Immunotherapeutics | AGrant or award Stock Option (Right to Buy)derivative | +520,342 | $0.00 | $0 | 520,342 | Jan 9, 2026 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | CConversion Class A ordinary shares, par value $0.0001 per share | +196,316 | - | - | 3,074,893 | Dec 22, 2025 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | DDisposition to issuer Class C ordinary shares, par value $0.0001 per share | -196,316 | - | - | 0 | Dec 22, 2025 |
| Dec 19, 2025 | MLTX MoonLake Immunotherapeutics | CConversion Common shares, par value CHF 0.10 per share, of MoonLake AGderivative | -5,836 | - | - | 0 | Dec 22, 2025 |
| Dec 8, 2025 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -130,000 | $15.08 | $2.0M | 2,948,577 | Dec 10, 2025 |
| Dec 9, 2025 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share | -70,000 | $14.49 | $1.0M | 2,878,577 | Dec 10, 2025 |
| Feb 27, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -62,810 | $55.00 | $3.5M | 3,043,619 | Feb 29, 2024 |
| Feb 28, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -56,065 | $55.00 | $3.1M | 2,987,554 | Feb 29, 2024 |
| Feb 29, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -4,740 | $55.89 | $265k | 2,982,814 | Feb 29, 2024 |
| Feb 21, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -1,125 | $55.27 | $62k | 3,106,429 | Feb 23, 2024 |
| Feb 15, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -20,000 | $60.18 | $1.2M | 3,147,554 | Feb 20, 2024 |
| Feb 16, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -20,000 | $60.15 | $1.2M | 3,127,554 | Feb 20, 2024 |
| Feb 20, 2024 | MLTX MoonLake Immunotherapeutics | SOpen-market sale Class A ordinary shares, par value $0.0001 per share10b5-1 | -20,000 | $57.44 | $1.1M | 3,107,554 | Feb 20, 2024 |
Questions about da Silva Jorge Santos
Answered from the filings on this page, as of the latest one.
Is da Silva Jorge Santos buying or selling?
In the last 12 months da Silva Jorge Santos reported 0 open-market buys worth $0 and 4 open-market sells worth $8.7M on SEC Form 4; the latest was sold $2.0M of MLTX on Jul 9, 2026. Grants, option exercises and tax withholding are not counted.
How did da Silva Jorge Santos's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and da Silva Jorge Santos has 0.
Where does da Silva Jorge Santos file Form 4?
da Silva Jorge Santos has filed Form 4 at MLTX (MoonLake Immunotherapeutics) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.